Despite efforts to individualize dosages, toxicity and efficacy outcomes of chemotherapy vary considerably among patients due to the highly variable and unpredictable biochemistry of the individual. Dosages based on monitoring drug concentration levels have been shown to improve therapeutic outcome of many chemo agents. Drug concentration level measurement in brain fluid provides clinicians feedback to ascertain toxicity level and optimize the administration of chemotherapeutics by adapting the dosage.


The MBP incorporates an on-board sensor which can be tuned to monitor varying concentrations of medications in the brain fluid.  This sensor has currently been tested and shown to be effective in monitoring drug concentrations in real time.



On-board Biofeedback 


After testing our sensor with known concentrations of a specific medication and comparing the results with those from a commercially available tabletop scanner, we found our sensor to be accurate. We performed in vitro tests with a closed circuit fluidic system where known amounts of methotrexate were added to liquid which was constantly being circulated past the sensor. The plot above shows that the sensor was able to accurately detect the concentration over time.



  • Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes, M. Wasif Saif, Adrienne Choma, Salvatore J. Salamone, Edward Chu, Journal of Clinical Investigation 2000; vol 105, issue 101: 1-10, 2009Available here.


  • Spectrophotometric Method for Determination of Methotrexate, Sildenafil Citrate and Trimetazidine Dihydrochloride in Pharmaceutical Formulations, J. K. Verma and H. A. Syed, Journal of Pharmacy Research 2010, 3(3),615-617Available here.